August 26, 2020Open Access

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Key Points

Abstract

Cite This Study